Tess E Peterson1, Jason V Baker2,3. 1. Division of Epidemiology and Community Health. 2. Department of Medicine, University of Minnesota. 3. Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: This article describes the use of biomarkers in expanding our understanding of chronic non-AIDS comorbidities among persons living with HIV (PLWH) receiving antiretroviral therapy (ART). RECENT FINDINGS: We review current evidence that biomarkers of chronic immune activation and inflammation associate with a broad spectrum of end-organ diseases in PLWH. We discuss how ART may impact inflammation associated with HIV infection and the degree to which inflammation persists despite effective suppression of viral replication in plasma. We then discuss the limitations of the current literature, which lacks evidence of causality and disproportionately involves a few protein biomarkers that are unable to disentangle complex and overlapping biological pathways. SUMMARY: Premature end-organ disease among PLWH has been repeatedly associated with higher levels of blood biomarkers reflecting inflammation and immune activation, which, despite viral suppression and CD4 T-cell increases after ART treatment, remain elevated relative to uninfected persons. There remain important unanswered questions with implications for the development of anti-inflammatory treatment strategies aimed at mitigating excess risk for end-organ comorbidities among PLWH.
PURPOSE OF REVIEW: This article describes the use of biomarkers in expanding our understanding of chronic non-AIDS comorbidities among persons living with HIV (PLWH) receiving antiretroviral therapy (ART). RECENT FINDINGS: We review current evidence that biomarkers of chronic immune activation and inflammation associate with a broad spectrum of end-organ diseases in PLWH. We discuss how ART may impact inflammation associated with HIV infection and the degree to which inflammation persists despite effective suppression of viral replication in plasma. We then discuss the limitations of the current literature, which lacks evidence of causality and disproportionately involves a few protein biomarkers that are unable to disentangle complex and overlapping biological pathways. SUMMARY:Premature end-organ disease among PLWH has been repeatedly associated with higher levels of blood biomarkers reflecting inflammation and immune activation, which, despite viral suppression and CD4 T-cell increases after ART treatment, remain elevated relative to uninfected persons. There remain important unanswered questions with implications for the development of anti-inflammatory treatment strategies aimed at mitigating excess risk for end-organ comorbidities among PLWH.
Authors: Heather M Derry-Vick; Carrie D Johnston; Mark Brennan-Ing; Chelsie O Burchett; Nina Glesby; Yuan-Shan Zhu; Eugenia L Siegler; Marshall J Glesby Journal: Psychosom Med Date: 2022-07-27 Impact factor: 3.864
Authors: Heather M Derry; Carrie D Johnston; Chelsie O Burchett; Mark Brennan-Ing; Stephen Karpiak; Yuan-Shan Zhu; Eugenia L Siegler; Marshall J Glesby Journal: J Gerontol B Psychol Sci Soc Sci Date: 2022-01-12 Impact factor: 4.077
Authors: Archana Asundi; Alex Olson; Wenqing Jiang; Swati P Varshney; Laura F White; Manish Sagar; Nina H Lin Journal: AIDS Res Hum Retroviruses Date: 2022-01-10 Impact factor: 2.205
Authors: K M Emanuel; K Runner; Z D Brodnik; B M Morsey; B G Lamberty; H S Johnson; A Acharya; S N Byrareddy; R A España; H S Fox; P J Gaskill Journal: iScience Date: 2022-04-06
Authors: Eveline Verheij; Gregory D Kirk; Ferdinand W Wit; Rosan A van Zoest; Sebastiaan O Verboeket; Bregtje A Lemkes; Maarten F Schim van der Loeff; Peter Reiss Journal: J Infect Dis Date: 2020-08-17 Impact factor: 5.226